The Antidepressant Effects of the mGlu2/3 Receptor Antagonist TS-161 in Treatment-Resistant Depression
Mark D. Kvarta, Mai Watanabe, Satoshi Ozaki, Dede Greenstein et autres
0 citationsJournal of Clinical Psychopharmacology
Taisho Pharmaceutical (Japan)
Tokyo · JP · company
1855Publications signalées
191991Citations signalées
12Thèmes principaux
Principaux domaines
Neuroscience and Neuropharmacology ResearchReceptor Mechanisms and SignalingNeurotransmitter Receptor Influence on BehaviorAnalytical Chemistry and ChromatographyDrug Transport and Resistance MechanismsNeuropeptides and Animal PhysiologyTryptophan and brain disordersAldose Reductase and TaurineInflammatory mediators and NSAID effectsIon channel regulation and functionEicosanoids and Hypertension PharmacologyPharmacological Receptor Mechanisms and Effects
Évolution annuelle
Publications récentes
Long-term Safety and Efficacy of Vornorexant in Japanese Patients with Insomnia: A 52-week Open-Label, Randomized Trial
Naohisa Uchimura, Daiji Kambe, Sayaka Hasegawa, Yumiko Imadera et autres
0 citationsSleep Medicine
Modulating satiety with neuro-music: a frequency-specific acoustic approach to appetite control
Ming Chang, Takuya Ibaraki, Yoshihiro Oaku, Maki Hirate et autres
0 citationsFrontiers in Human Neuroscience
Cryo-EM elucidates the interaction mechanism of ozoralizumab, a humanized anti-TNFα NANOBODY® compound
Masashi Mima, K Sato, Takeshi Yokoyama, Chiemi Mishima-Tsumagari et autres
0 citationsBiochemical and Biophysical Research Communications
Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial)
Yuki Imai, M. Kono, Tomonori Ishii, T. Kojima et autres
3 citationsAnnals of the Rheumatic Diseases
Efficacy of ozoralizumab in rheumatoid arthritis patients with large joint involvement: a post hoc analysis of OHZORA and NATSUZORA trials
Kosuke Ebina, Shunsuke Okamoto, Masanao Kyuuma, Nobuko Horiuchi et autres
0 citationsRMD Open
Driving performance in the morning after bedtime vornorexant administration: A randomized clinical trial using a driving simulator
Yusuke Miyazaki, Kunihiro Iwamoto, Daiji Kambe, Yumiko Imadera et autres
3 citationsPsychiatry and Clinical Neurosciences
Network analysis reveals causal relationships among individual background risk factors leading to influenza susceptibility
Akihide Terada, Kenji Fujimoto, Kazuyoshi Kise, Eiichiro Uchino et autres
3 citationsScientific Reports
Use of 5% Topical Minoxidil Application for Telogen Effluvium: An Open‐Label Single‐Arm Clinical Trial
Manabu Ohyama, Ryokichi Irisawa, M Uchiyama, Miho Mori et autres
1 citationThe Journal of Dermatology
LB0006 SPACING OF A TNF BLOCKER AND DOSE REDUCTION OF METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN REMISSION OR LOW DISEASE ACTIVITY WITH OZORALIZUMAB AND METHOTREXATE: A RANDOMISED, CONTROLLED TRIAL (SORAIRO TRIAL)
Yuki Imai, T. Atsumi, Taeko Ishii, T. Kojima et autres
0 citationsAnnals of the Rheumatic Diseases
POS0688 EFFICACY OF OZORALIZUMAB BASED ON BASELINE RF TITRES IN PATIENTS WITH RA: A POST HOC ANALYSIS OF THE OHZORA TRIAL
R. Watanabe, Y. Tanaka, Tohru Takeuchi, Shizuko Okamoto et autres
0 citationsAnnals of the Rheumatic Diseases
ABS0269 LPA1/3 DUAL ANTAGONIST AMELIORATED SYSTEMIC SCLEROSIS MORE EFFECTIVE THAN LPA1 SELECTIVE ANTAGONIST VIA SUPPRESSING LPA3 PATHWAY IN SKIN
Takumi Naruse, Lucas Miyake Okumura, Hiroaki Kajiyama, Yoji Nagashima et autres
0 citationsAnnals of the Rheumatic Diseases
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.